Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
Comparison of the Effect of Exenatide vs. Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
Texas
-
San Antonio, Texas, Estados Unidos
- Research Site
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Have type 2 diabetes
- Has HbA1c 7.0% to 11.0%, at or within 4 weeks prior to Visit 1.
- Have a fasting glucose concentration <280 mg/dL at Visit 1
- Have been treated with a stable dose of immediate or extended release metformin for at least 60 days prior to screening OR TZD (rosiglitazone or pioglitazone) for at least 120 days prior to screening.
- Are between 18 and 70 years of age, inclusive.
- Have body mass index ≥25 kg/m2 and ≤45 kg/m2.
- Have a history of stable body weight (not varying by >10% for at least 3 months prior to screening).
- Can swallow oral study drug capsule, without splitting or crushing.
Exclusion Criteria:
Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who meet any of the following criteria:
- Are breastfeeding.
- Test positive for pregnancy at the time of screening.
- Intend to become pregnant during the study.
- Have not practiced a reliable method of birth control (for example, use of oral contraceptives or Norplant®; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for 3 months prior to screening.
Treated with any of the following medications:
- Insulin, exenatide, pramlintide, sulfonylureas or meglitinides within 3 months of screening
- Alpha-glucosidase inhibitor within 2 months of screening.
- Drugs that directly affect gastrointestinal motility, including, but not limited to metoclopramide, cisapride, and chronic macrolide antibiotics.
- Use of a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phentermine, or similar over-the-counter medications) within 3 months prior to Visit 1.
- Systemic corticosteroids by oral, intravenous, or intramuscular route within 2 months of screening.
- Have a history of renal transplantation or are currently receiving renal dialysis.
- Have obvious clinical signs or symptoms of liver disease or acute or chronic hepatitis.
- Have known active proliferative retinopathy or macular edema expected to need treatment with focal photocoagulation within 3 months.
- Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
- Have had organ transplantation.
- Have received GLP-1 analogs other than exenatide or DPP-4 inhibitors within the previous 3 months.
- Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Dobro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Sequência A
|
injeção subcutânea (5mcg ou 10mcg), duas vezes ao dia
Outros nomes:
administração oral (100mg), uma vez ao dia pela manhã
Outros nomes:
subcutaneous injection (5mcg or 10mcg), twice a day
oral administration (100mg), once a day in the morning
|
|
Experimental: Sequência B
|
injeção subcutânea (5mcg ou 10mcg), duas vezes ao dia
Outros nomes:
administração oral (100mg), uma vez ao dia pela manhã
Outros nomes:
subcutaneous injection (5mcg or 10mcg), twice a day
oral administration (100mg), once a day in the morning
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Time-averaged Glucose During a 24 Hour Period
Prazo: baseline and 8 Weeks
|
Change in time-averaged glucose during a 24-hour period from baseline to endpoint (i.e., time-averaged glucose over 24 hours at endpoint minus time-averaged glucose over 24 hours at baseline).
|
baseline and 8 Weeks
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Two-hour Postprandial Glucose After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in 2 hour post-prandial glucose after the morning meal from baseline to endpoint (i.e., glucose level 2 hours after the morning meal at baseline minus glucose level 2 hours after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Fasting Blood Glucose After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in fasting blood glucose after the morning meal from baseline to endpoint (i.e., fasting blood glucose after the morning meal at baseline minus fasting blood glucose after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Glucagon Area Under the Concentration-time Curve (AUC) After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in Postprandial Glucagon AUC after the morning meal (t=0 to 4 hours) (i.e., Glucagon AUC over the first 4 hours following the morning meal at baseline minus glucagon AUC over the first 4 hours following the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Glucagon AUC Excursion After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in postprandial glucagon AUC excursion after the morning meal (t=0 to 4 hours) (i.e., glucagon AUC excursion for 4 hours following the morning meal at baseline minus glucagon AUC excursion for 4 hours following the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Triglyceride AUC After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in postprandial triglyceride AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC after the morning meal at baseline minus postprandial triglyceride AUC after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Triglyceride AUC Excursion After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in postprandial triglyceride AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC excursion after the morning meal at baseline minus postprandial triglyceride AUC excursion after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial C-peptide AUC After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in postprandial C-peptide AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC after the morning meal at baseline minus postprandial C-peptide AUC after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial C-peptide AUC Excursion After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in Postprandial C-peptide AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC excursion after the morning meal at baseline minus postprandial C-peptide AUC excursion after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Insulin AUC After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in postprandial insulin AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC after the morning meal at baseline minus postprandial insulin AUC after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Insulin AUC Excursion After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in Postprandial insulin AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC excursion after the morning meal at baseline minus postprandial insulin AUC excursion after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Active GLP-1 AUC After the Morning Meal
Prazo: baseline and 8 Weeks
|
Change in Postprandial active GLP-1 AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC after the morning meal at baseline minus postprandial active GLP-1 AUC after the morning meal at endpoint)
|
baseline and 8 Weeks
|
|
Change in Postprandial Active GLP-1 AUC Excursion After the Monrning Meal
Prazo: baseline and 8 Weeks
|
Change in Postprandial active GLP-1 AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC excursion after the morning meal at baseline minus postprandial active GLP-1 AUC excursion after the morning meals at endpoint)
|
baseline and 8 Weeks
|
|
Percentage of Patients Experiencing Hypoglycemia (Baseline to Week 4)
Prazo: 4 Weeks
|
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
|
4 Weeks
|
|
Episodes of Hypoglycemia (Baseline to Week 4)
Prazo: 4 weeks
|
Number of episodes of hypoglycemia experienced during the first 4 weeks of the study
|
4 weeks
|
|
Percentage of Patients Experiencing Hypoglycemia (Week 4 to Week 8)
Prazo: 8 weeks
|
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
|
8 weeks
|
|
Episodes of Hypoglycemia (Week 4 to Week 8)
Prazo: 8 weeks
|
Number of episodes of hypoglycemia experienced between week 4 and week 8 of the study
|
8 weeks
|
|
Percentage of Patients Experiencing Hypoglycemia (Overall)
Prazo: 4 weeks and 8 weeks
|
Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL
|
4 weeks and 8 weeks
|
|
Episodes of Hypoglycemia (Overall)
Prazo: 4 weeks and 8 weeks
|
Number of episodes of hypoglycemia experienced overall during the study
|
4 weeks and 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Distúrbios do Metabolismo da Glicose
- Doenças Metabólicas
- Doenças do Sistema Endócrino
- Diabetes Mellitus
- Diabetes Mellitus, Tipo 2
- Hipoglicemiantes
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Hormônios
- Hormônios, Substitutos Hormonais e Antagonistas Hormonais
- Inibidores de Protease
- Agentes Anti-Obesidade
- Incretinas
- Inibidores de Dipeptidil-Peptidase IV
- Fosfato de Sitagliptina
- Exenatida
Outros números de identificação do estudo
Outros números de identificação do estudo
- H8O-US-GWCV
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .